Compare Abbott Laboratories (ABT) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Realty Income Corp — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Realty Income Corp trades at $63.48 (market cap $59.69B). The key difference: Abbott Laboratories is far larger — about 2.8× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.08%). Which is the better fit depends on your goals.
| ABT | O | |
|---|---|---|
Market Cap | $166.94B | $59.69B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $67.56 |
52-Week Low | $82.57 | $55.93 |
Enterprise Value | $193.69B | $89.49B |
Dividend Yield | 2.63% | 5.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Realty Income (O) trades at $64.01, up 0.27% with a bullish technical signal from moving averages. The REIT maintains strong fundamentals with $5.75B revenue (2025), 92.54% gross margins, and consistent monthly dividends. Recent earnings missed expectations for three consecutive quarters, but analyst consensus remains positive with a $67.86 price target. Operating cash flow grew to $4.0B in 2025, though debt-to-asset ratio increased to 39.93%.
Outlook remains stable with dividend reliability as a key strength, but elevated P/E (51.8) and recent earnings misses pose valuation concerns. Risks include rising leverage and interest rate sensitivity. Institutional sentiment leans bullish (41% buy ratings), supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
